ArticleBreast cancer research : BCR2021
In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study.
Article in Breast cancer research : BCR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Pathologic complete response and survival according to germline BRCA1/2 status in triple-negative breast cancer.Breast cancer (Tokyo, Japan) · 2026Article
- Enhanced recurrence risk stratification for stages Ⅱ-Ⅲ breast cancer using MRI-based structure habitat imaging.European radiology · 2026Article
- Ten-year survival of women with invasive breast cancer by stage, molecular subtype, and grade combined: a population-based study.The oncologist · 2026Article
- Breast Cancer Liver Metastasis: Primary tumor predictors and histopathologic characteristics of metastatic lesions.Research square · 2026Article
- A nationwide population-based study on the incidence and prognosis of HER2-positive breast cancer eligible for adjuvant pertuzumab in the modern era of neoadjuvant therapy.Breast (Edinburgh, Scotland) · 2026Article
- Breast cancer in Bosnia and Herzegovina: real-world patterns of diagnosis, treatment, and survival outcomes.Scientific reports · 2026Article
- Nomogram prediction for breast cancer-specific survival in patients with ERTranslational cancer research · 2026Article
- Multi-omics deep learning improves FDG PET-CT-based long-term prognostication of breast cancer.NPJ precision oncology · 2026Article
- Correlation of quantitative background parenchymal enhancement with prognostic factors in breast cancer.Frontiers in oncology · 2026Article
- A pilot study of multimodal MRI for the preoperative assessment of triple-negative breast cancer.Frontiers in oncology · 2026Article
- Postmastectomy radiotherapy in pN1 breast cancer: Survival outcomes and prognostic factors from a single-institution cohort.PloS one · 2026Article
- Dynamic vitamin D trajectories and their prognostic value in breast cancer: a group-based trajectory modeling study.Frontiers in nutrition · 2026Article
- Diagnostic value of peripheral blood inflammatory indices for breast cancer grade and immunohistochemical markers: a retrospective observational study.BMC cancer · 2025Observational
- Loss of BPTF restores estrogen response and suppresses metastasis of mammary tumors.Nature communications · 2025Article
- Lamin A/C as a biomarker for breast cancer.Molecular biology reports · 2025Review
- Enhancing breast cancer diagnosis through machine learning algorithms.Scientific reports · 2025Article
- Extending catchment area approaches to a community cancer center: a breast cancer hotspot case study.JNCI cancer spectrum · 2025Article
- Long-term Outcomes of Early Breast Cancer Stratified by Axillary Ultrasound Assessment.Journal of breast cancer · 2025Article
- Clinical Significance of Tumor Grade in Triple-Negative Breast Cancer: A Retrospective Cohort Analysis.Biomedicines · 2025Article
- Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer.JAMA network open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn breast cancer, immunohistochemistry (IHC) subtypes, together with grade and stage, are well-known independent predictors of breast cancer death. Given the immense changes in breast cancer treatment and survival over time, we used recent population-based data to test the combined influence of IHC subtypes, grade and stage on breast cancer death.
methodsWe identified 24,137 women with invasive breast cancer aged 20 to 74 between 2005 and 2015 in the database of the Cancer Registry of Norway. Kaplan-Meier curves, mortality rates and adjusted hazard ratios for breast cancer death were estimated by IHC subtypes, grade, tumour size and nodal status during 13 years of follow-up.
resultsWithin all IHC subtypes, grade, tumour size and nodal status were independent predictors of breast cancer death. When combining all prognostic factors, the risk of death was 20- to 40-fold higher in the worst groups compared to the group with the smallest size, low grade and ER+PR+HER2- status. Among node-negative ER+HER2- tumours, larger size conferred a significantly increased breast cancer mortality. ER+PR-HER2- tumours of high grade and advanced stage showed particularly high breast cancer mortality similar to TNBC. When examining early versus late mortality, grade, size and nodal status explained most of the late (> 5 years) mortality among ER+ subtypes.
conclusionsThere is a wide range of risks of dying from breast cancer, also across small breast tumours of low/intermediate grade, and among node-negative tumours. Thus, even with modern breast cancer treatment, stage, grade and molecular subtype (reflected by IHC subtypes) matter for prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.